NVS - Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B | Benzinga
Monday, Novartis AG (NYSE:NVS) made a voluntary public takeover offer to acquire MorphoSys AG (NASDAQ:MOR) for €68 per share (or an aggregate of €2.7 billion), expanding and complementing Novartis pipeline in oncology while also enhancing Novartis global footprint in hematology.
As part of the agreement, Novartis will own pelabresib (CPI-0610), an investigational treatment option with a well-tolerated safety profile provided in combination with ruxolitinib for patients with myelofibrosis.
It will also include tulmimetostat (CPI-0209), an early-stage investigational dual inhibitor of enhancer of zeste homolog 1 and 2 (EZH1 and EZH2) ...